fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Ethambutol HCL

2 general benefit · 2 not a benefit

Etibi · DIN 00247960 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Etibi · DIN 00247960 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2019-07-10 · brand ETIBI · ATC J04AK02 ETHAMBUTOL · form Tablet · route Oral · ingredients ETHAMBUTOL HYDROCHLORIDE 100 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Etibi: Formulary list price $0.28 per unit (the source does not state the unit; exact figure $0.2840). What the ministry pays, not the patient.

Ministry pays: $0.2840 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00247960)

Source record
DIN 00247960: Etibi Raw flags: sec3=Y Item: 081600004; group id 55; item number 0112; lccId None; manufacturer id VAL Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2840; ministry $0.2840 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00247960 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1471
Interchangeable products
Myambutol · DIN 00127957 · not recorded
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00247960
Shortage record checked October 6, 2026

Etibi · DIN 00247979 · 400 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Etibi · DIN 00247979 Manufacturer: Valeant Canada Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2019-07-10 · brand ETIBI · ATC J04AK02 ETHAMBUTOL · form Tablet · route Oral · ingredients ETHAMBUTOL HYDROCHLORIDE 400 MG · company Bausch health, canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Etibi: Formulary list price $0.85 per unit (the source does not state the unit; exact figure $0.8522). What the ministry pays, not the patient.

Ministry pays: $0.8522 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00247979)

Source record
DIN 00247979: Etibi Raw flags: sec3=Y Item: 081600003; group id 55; item number 0113; lccId None; manufacturer id VAL Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.8522; ministry $0.8522 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00247979 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=1472
Interchangeable products
Myambutol · DIN 02170078 · not recorded
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00247979
Shortage record checked October 6, 2026

Myambutol · DIN 00127957 · 100 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-01-14 — choose a marketed DIN from the same-category list.Discontinued January 14, 1997 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1997-01-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 1997-01-14 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Myambutol · DIN 00127957 Manufacturer: Lederle Division-of Cyanamid Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 1997-01-14 · brand MYAMBUTOL TAB 100MG · ATC J04AK02 ETHAMBUTOL · form Tablet · route Oral · ingredients ETHAMBUTOL HYDROCHLORIDE 100 MG/TAB · company Lederle cyanamid canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Myambutol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00127957)

Source record
DIN 00127957: Myambutol Raw flags: notABenefit=Y, sec3=Y Item: 081600004; group id 55; item number 0112; lccId None; manufacturer id LED Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00127957 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=699
Interchangeable products
Etibi · DIN 00247960 · $0.2840
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00127957
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 14, 1997 — choose a marketed DIN from the same-category list.

Myambutol · DIN 02170078 · 400 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-02-06 — choose a marketed DIN from the same-category list.Discontinued February 6, 2002 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2002-02-06 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2002-02-06 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Myambutol · DIN 02170078 Manufacturer: Wyeth Pharmaceuticals; listing date 1997-02-04 Health Canada: Cancelled post market since 2002-02-06 · brand MYAMBUTOL TABLETS - 400 MG · ATC J04AK02 ETHAMBUTOL · form Tablet · route Oral · ingredients ETHAMBUTOL HYDROCHLORIDE 400 MG · company Wyeth-ayerst canada inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Myambutol: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02170078)

Source record
DIN 02170078: Myambutol Raw flags: notABenefit=Y, sec3=Y Item: 081600003; group id 55; item number 0113; lccId None; manufacturer id WAY Source form: Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02170078 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=34567
Interchangeable products
Etibi · DIN 00247979 · $0.8522
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02170078
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 6, 2002 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J04A): coverage varies; not interchangeable

  • Rifampin (Rofact): general benefit
  • Rifabutin (Mycobutin): limited Use 103, 104, listing status unconfirmed
Other drugs in the same formulary class (08:16 Antitubercular Agents) and how they are covered

Matched class: 08:16 Antitubercular Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: RIFAMPIN 08:16 Antitubercular Agents

RIFAMPIN

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

RIFABUTIN

· 2 products · Limited Use, codes 103, 104 (1), Temporary benefit (1) · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:16
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications ETIBI (ethambutol) is indicated in combination with other antituberculosis medications for: • Treatment of all forms of tuberculosis, including tuberculous meningitis, caused by Mycobacterium tuberculosis. In retreatment cases, Etibi should be given together with at least one other second line drug for which bacterial susceptibility has been indicated by appropriate in vitro studies and which has not been administered previously to the patient. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Etibi Tablets and other antibacterial drugs, Etibi Tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 1.1. Pediatrics Pediatrics (˂ 13 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2. Geriatrics It is unknown if … https://pdf.hres.ca/dpd_pm/00082029.PDF PM date: not printed or not captured Source product: ETIBI; DIN 00247960; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Myambutol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026